Mankind Pharma Limited

BSE: 543904 NSE: MANKIND
Mankind Pharma Limited - pharma in New Delhi, Delhi, India. FY 2026 financials & compliance.
CIN L74899DL1991PLC044843 Incorporated 03 July 1991 ROC Delhi HQ New Delhi, Delhi, India
Active Listed - NSE: MANKIND · BSE: 543904 Public Limited Company pharma Fortune India 500 · #210 Nifty 500
Data last updated
Market Cap
₹91,390 Cr
MANKIND · NSE
Share Price
₹2,312.00
+4.49% today
Revenue
₹14,278 Cr
FY 2025-26 · +17.0% YoY
EBITDA
₹3,493 Cr
Margin 24.5%
Net Profit
₹2,014 Cr
FY 2025-26 · +12.2% YoY
P/E (TTM)
42.8x
P/B 5.6x
ROE
12.7%
ROCE 13.0%
Debt / Equity
0.48
Interest cover 24.7x

About Mankind Pharma Limited

Data last updated:

Mankind Pharma Limited is a public limited company based in New Delhi, Delhi, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 03 July 1991 and has been in existence for over 35 years.

Mankind Pharma is ranked #210 on the Fortune India 500 (2025). It is part of the Nifty 500 and BSE 500 indices. Its director Ramesh Juneja and family are #115 among India's richest people (2026). Its director Rajeev Juneja and family are #119 among India's richest people (2026).

The company is registered with the Registrar of Companies (ROC), Delhi, under CIN L74899DL1991PLC044843. Its GSTIN is 07AAACM9401C1ZX (Delhi). The company holds 35 GST registrations, of which 29 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 543904 and NSE: MANKIND.

The company has an authorised share capital of ₹421.51 Cr and a paid-up capital of ₹41.3 Cr. It was formerly known as Mankind Pharma Private Limited. It is led by directors including Rajeev Juneja (Managing Director) and Sheetal Arora (Whole-Time Director).

Its last annual general meeting (AGM) was held on 04 August 2026, and its latest financial statements are for the year ended 31 March 2026. The registered office is at 208 Okhla Industrial Estate Phase – III, New Delhi, Delhi, India – 110020.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹14,278 Cr, a growth of 17% compared to the previous year. For the same year it recorded a net profit of ₹2,014.45 Cr (net margin 14.1%) and EBITDA of ₹3,492.63 Cr (EBITDA margin 24.5%). The net worth stands at ₹16,300 Cr (up 13.7% YoY). Total assets are valued at ₹23,151 Cr (down 0.4% YoY).

The company has about 19,928 employees on its provident fund (EPFO) records. Its group structure includes 22 subsidiaries.

The company is associated with 3 brands: Mediforce Healthcare, Manforce Condoms and Mankind Pharma. As per MCA filings, the company has open charges of ₹4,915 Cr and satisfied charges of ₹7,758.37 Cr on record. Court records list 622 cases involving the company, including 537 filed by the company and 85 filed against it; 232 cases are pending. The company has 29 deals on record (14 secondary share transfers, 12 market trades, 1 funding round), with disclosed funding of ₹74.05 Cr; the latest was in October 2025. The company has 3 MSME Form 1 returns on record between 2021 and 2024, listing 998 overdue payments to 142 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website mankindpharma.com.

Company details

CIN L74899DL1991PLC044843
Registration Number 044843
Incorporation Date 03 July 1991
ROC Delhi
Listing Status Listed - Listed on NSE (MANKIND); Listed on BSE (543904)
Company Status Active
Date of Last AGM 04 August 2026
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant

CIN history

Mankind Pharma has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L74899DL1991PLC044843, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L74899DL1991PLC044843Current
U74899DL1991PLC044843Previous
U74899DL1991PTC044843Previous
Key People
Rajeev Juneja Managing Director Sheetal Arora Whole-Time Director Satish Kumar Sharma Whole-Time Director

Recognitions & Rankings of Mankind Pharma

Fortune India 500 2025 edition
Rank#210
Total income
₹12,944 Cr
Profit
₹1,991 Cr
Last year #227
India's Most Valuable Companies 2024 edition · Source: Hurun India
Rank#60
Valuation
₹1,05,770 Cr
2023 #60 2022 #84 2021 #109
Stock market indices
Nifty 500 BSE 500

Contact details

Mankind Pharma Limited's registered office is in New Delhi, Delhi. Its website is mankindpharma.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    mankindpharma.com
  • Social Media
  • Registered Address
    208 Okhla Industrial Estate Phase – III, New Delhi, Delhi, India – 110020
  • Industry
    Pharma, Drug Formulation & Development

To see the full contact details of Mankind Pharma Limited, buy the company report.

Comprehensive company report
Mankind Pharma Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Mankind Pharma operates multiple associated brands including Mediforce Healthcare, Manforce Condoms, and Mankind Pharma. Each brand links to its own profile.

BrandDescriptionWebsite
Mediforce Healthcare
Manufactures and distributes a range of medicines and healthcare products.mediforcehealthcare.com
Manforce Condoms
Condom manufacturing and sexual health resources in India.manforcecondoms.com
Mankind Pharma
Pharmaceutical company engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulationsmankindpharma.com

Business activity

The main business activities of Mankind Pharma are trade and manufacturing. In detail, this covers wholesale trading and chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products. 2 activity segments are registered with the MCA.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
GTradeG1Wholesale Trading
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products

To see the full business activity and turnover split of Mankind Pharma Limited, buy the company report.

Financials of Mankind Pharma Limited

FY 2025-26 filings available

Mankind Pharma Limited reported revenue of ₹14,278 Cr (up 17% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹14,278 Cr
+17.0% YoY
EBITDA
₹3,493 Cr
+15.6% YoY
Profit After Tax
₹2,014 Cr
+12.2% YoY
Net Worth
₹16,300 Cr
+13.7% YoY
Total Assets
₹23,151 Cr
-0.4% YoY
Total Debt
₹6,312 Cr
-25.8% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue14,27812,20710,2608,7497,7826,2145,865
Revenue growth+17.0%+19.0%+17.3%+12.4%+25.2%+6.0%-
EBITDA3,4933,0202,5151,9021,9911,6491,438
EBITDA margin+24.5%+24.7%+24.5%+21.7%+25.6%+26.5%+24.5%
Profit before tax2,3332,5212,3991,6711,9751,6921,438
Net profit2,0141,7961,8071,2531,3691,217998
Net profit margin+14.1%+14.7%+17.6%+14.3%+17.6%+19.6%+17.0%
EPS (₹)1,913.0648.2547.7532.0035.7831.5925.72
Balance sheet
Total assets23,15123,2559,9297,9177,2905,1853,884
Net worth16,30014,3329,3637,4356,1554,7223,485
Total debt6,3128,511207170873241131
Cash & bank483554708453406701420
Net working capital2,3292,6052,3651,5311,7301,426976
Cash flow
Cash from operations3,1212,4132,1521,8139201,1371,070
Cash from investing(181)(12,624)(2,081)(1,052)(1,369)(1,222)(436)
Cash from financing(2,953)10,2335.27(740)605(7.81)(531)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue4,0313,4433,5673,6973,5703,0793,1993,061
Revenue growth (YoY)+12.9%+11.8%+11.5%+20.8%+24.5%---
Other income48.9411775.9694.1983.0525487.09112
EBITDA1,056907813921847679816845
EBITDA margin+26.2%+26.3%+22.8%+24.9%+23.7%+22.0%+25.5%+27.6%
Depreciation226223223222219231187100
Interest1101421571701711912217.10
Profit before tax769659509624540511495849
Tax19599.7595.1210495.8786.44110190
Net profit574559414520445425385659
EPS (₹)13.7413.419.8912.3810.6010.189.4416.28
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue10,4219,5078,6298,1277,4865,5304,794
Revenue growth+9.6%+10.2%+6.2%+8.6%+35.4%+15.3%-
EBITDA2,9802,4252,2671,6981,8381,3791,244
EBITDA margin+28.6%+25.5%+26.3%+20.9%+24.6%+24.9%+26.0%
Profit before tax2,3152,2082,2891,5631,8711,4401,265
Net profit2,1251,6051,7701,2191,3271,054940
Net profit margin+20.4%+16.9%+20.5%+15.0%+17.7%+19.1%+19.6%
EPS (₹)49.3643.2946.8331.1634.6827.0723.92
Balance sheet
Total assets22,19421,8379,8517,8987,3174,8983,715
Net worth16,39714,3239,7037,7846,5404,7343,651
Total debt5,5717,38323.504.696881012.56
Cash & bank159306484155139477198
Net working capital7035581,7911,0381,3611,212739
Cash flow
Cash from operations2,7522,3501,7361,7998211,022960
Cash from investing(388)(12,178)(1,665)(1,041)(1,360)(1,127)(396)
Cash from financing(2,477)9,816(4.73)(710)57988.87(559)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue2,9642,5822,6332,6092,5702,1192,4142,544
Revenue growth (YoY)+15.3%+21.8%+9.0%+2.5%+6.5%---
Other income33.9612756.5277.6765.2122070.37139
Total expenses2,0351,6861,9381,9161,8851,7781,6681,781
EBITDA929896695693685342746763
EBITDA margin+31.3%+34.7%+26.4%+26.6%+26.7%+16.1%+30.9%+30.0%
Depreciation11110910899.0310511591.1190.33
Interest94.951251381471491622002.61
Profit before tax757788505525496284525810
Tax19874.4056.4165.7380.9046.29113165

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 26 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue4,0313,4433,5673,6973,5703,0793,1993,061
Revenue growth (YoY)+12.9%+11.8%+11.5%+20.8%+24.5%---
Other income48.9411775.9694.1983.0525487.09112
EBITDA1,056907813921847679816845
EBITDA margin+26.2%+26.3%+22.8%+24.9%+23.7%+22.0%+25.5%+27.6%
Depreciation226223223222219231187100
Interest1101421571701711912217.10
Profit before tax769659509624540511495849
Tax19599.7595.1210495.8786.44110190
Net profit574559414520445425385659
EPS (₹)13.7413.419.8912.3810.6010.189.4416.28
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue14,27812,20710,2608,7497,7826,2145,865
Revenue growth+17.0%+19.0%+17.3%+12.4%+25.2%+6.0%-
Other income370554296141210183122
Total expenses10,7859,1877,7456,8485,7914,5654,427
Employee cost3,1842,6922,2611,9181,6211,4161,336
EBITDA3,4933,0202,5151,9021,9911,6491,438
EBITDA margin+24.5%+24.7%+24.5%+21.7%+25.6%+26.5%+24.5%
Depreciation88662137832616711999.06
Interest64443234.2445.7659.8021.1623.24
Profit before tax2,3332,5212,3991,6711,9751,6921,438
Tax395510457362522399382
Net profit2,0141,7961,8071,2531,3691,217998
Net profit margin+14.1%+14.7%+17.6%+14.3%+17.6%+19.6%+17.0%
EPS (₹)1,913.0648.2547.7532.0035.7831.5925.72
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital41.2841.2640.0640.0640.0640.0640.06
Reserves & surplus16,25914,2919,3237,3956,1154,6823,445
Shareholders' funds (net worth)16,30014,3329,3637,4356,1554,7223,485
Minority interest261236213188161141186
Secured loans5,7656,026196163804224114
Unsecured loans5472,48511.137.7368.7517.1416.68
Total debt6,3128,511207170873241131
Total liabilities23,15123,2559,9297,9177,2905,1853,884
Assets
Gross block21,37720,9175,9155,2394,2522,1661,993
Net block18,62019,0054,5454,2513,5881,6641,600
Capital work in progress1,128826282550701372317
Investments1,9852,0422,5681,3461,1091,512829
Inventories2,1442,0941,5531,4981,7601,184899
Sundry debtors1,7301,538848576388331531
Cash & bank balances483554708453406701420
Loans & advances1,0601,1111,200724978386307
Total current assets5,4175,2974,3103,2523,5322,6002,157
Total current liabilities3,0882,6921,9451,7211,8031,1751,181
Net working capital2,3292,6052,3651,5311,7301,426976
Total assets23,15123,2559,9297,9177,2905,1853,884
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash404382305283127220116
Net cash from operating activities3,1212,4132,1521,8139201,1371,070
Net cash from investing activities(181)(12,624)(2,081)(1,052)(1,369)(1,222)(436)
Net cash from financing activities(2,953)10,2335.27(740)605(7.81)(531)
Net change in cash(12.19)21.8777.1921.76156(92.40)103
Closing cash483554708453406701420
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+17.0%+19.0%+17.3%+12.4%+25.2%+6.0%-
EBITDA growth+15.6%+20.1%+32.2%-4.5%+20.7%+14.7%-
PBT growth-7.5%+5.1%+43.5%-15.4%+16.7%+17.7%+131.5%
Net income growth+12.2%-0.6%+44.2%-8.5%+12.5%+22.0%-
Revenue CAGR (3Y)+17.7%+16.2%+18.2%+14.3%+32.7%--
EBITDA CAGR (3Y)+22.5%+14.9%+15.1%+9.8%+50.3%--
Profitability & leverage
Net income margin+13.6%+16.5%+18.9%+15.0%+18.7%+20.8%+18.0%
Return on capital employed+13.0%+18.0%+27.9%+23.1%+33.4%+39.2%+39.5%
Return on net worth+12.7%+17.0%+23.1%+19.3%+26.7%+31.5%+30.3%
Debt / equity0.480.370.020.080.100.050.04
Long-term debt / equity0.280.240.000.010.010.010.01
Interest cover24.7218.001.602.903.281.381.74
Efficiency & per share
Fixed asset turnover0.680.911.841.842.432.992.94
Inventory turnover6.746.696.725.375.295.976.52
Debtors turnover8.7410.2314.4018.1421.6514.4211.04
EPS (₹)1,913.0648.2547.7532.0035.7831.5925.72
Dividend per share (₹)1.000.000.000.000.007.600.00
Book value per share (₹)16,301.46347.37233.73185.61153.65117.8887.00
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue2,9642,5822,6332,6092,5702,1192,4142,544
Revenue growth (YoY)+15.3%+21.8%+9.0%+2.5%+6.5%---
Other income33.9612756.5277.6765.2122070.37139
Total expenses2,0351,6861,9381,9161,8851,7781,6681,781
EBITDA929896695693685342746763
EBITDA margin+31.3%+34.7%+26.4%+26.6%+26.7%+16.1%+30.9%+30.0%
Depreciation11110910899.0310511591.1190.33
Interest94.951251381471491622002.61
Profit before tax757788505525496284525810
Tax19874.4056.4165.7380.9046.29113165
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue10,4219,5078,6298,1277,4865,5304,794
Revenue growth+9.6%+10.2%+6.2%+8.6%+35.4%+15.3%-
Other income32655537416320414893.85
Total expenses7,4417,0826,3626,4295,6484,1513,550
Employee cost2,3672,1491,9211,7011,4631,106991
EBITDA2,9802,4252,2671,6981,8381,3791,244
EBITDA margin+28.6%+25.5%+26.3%+20.9%+24.6%+24.9%+26.0%
Depreciation42939533527012378.1961.77
Interest56237816.9328.2347.548.2311.10
Profit before tax2,3152,2082,2891,5631,8711,4401,265
Tax277422413315482356307
Net profit2,1251,6051,7701,2191,3271,054940
Net profit margin+20.4%+16.9%+20.5%+15.0%+17.7%+19.1%+19.6%
EPS (₹)49.3643.2946.8331.1634.6827.0723.92
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital41.2841.2640.0640.0640.0640.0640.06
Reserves & surplus16,35614,2819,6637,7446,5004,6943,611
Shareholders' funds (net worth)16,39714,3239,7037,7846,5404,7343,651
Secured loans5,4885,44414.930.0062495.000.00
Unsecured loans82.521,9398.574.6964.235.852.56
Total debt5,5717,38323.504.696881012.56
Total liabilities22,19421,8379,8517,8987,3174,8983,715
Assets
Gross block5,8915,6584,5783,7763,2921,2271,117
Net block3,9264,0763,5523,1422,927987945
Capital work in progress420207209495387166148
Investments16,52316,6834,2153,1022,5262,3971,784
Inventories1,0881,0981,1261,0321,267827533
Sundry debtors1,164909769493471369419
Cash & bank balances159306484155139477198
Loans & advances7248491,0117751,071521404
Total current assets3,1353,1623,3902,4552,9472,1941,554
Total current liabilities2,4322,6041,5991,4181,586982816
Net working capital7035581,7911,0381,3611,212739
Total assets22,19421,8379,8517,8987,3174,8983,715
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash20121214586.1746.3677.5072.48
Net cash from operating activities2,7522,3501,7361,7998211,022960
Net cash from investing activities(388)(12,178)(1,665)(1,041)(1,360)(1,127)(396)
Net cash from financing activities(2,477)9,816(4.73)(710)57988.87(559)
Net change in cash(113)(10.96)66.1647.9639.81(15.96)5.02
Closing cash159306484155139477198
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+9.6%+10.2%+6.2%+8.6%+35.4%+15.3%-
EBITDA growth+22.9%+7.0%+33.5%-7.7%+33.4%+10.8%-
PBT growth+4.9%-3.5%+46.5%-16.5%+29.9%+13.9%+83.0%
Net income growth+32.4%-9.3%+45.2%-8.2%+25.9%+12.2%-
Revenue CAGR (3Y)+8.6%+8.3%+16.0%+19.2%+25.0%+12.2%+11.1%
EBITDA CAGR (3Y)+20.6%+9.7%+18.0%+10.9%+37.7%+21.0%+21.1%
Profitability & leverage
Net income margin+19.6%+18.8%+21.7%+15.4%+18.6%+19.6%+20.0%
Return on capital employed+13.1%+16.3%+23.4%+20.9%+31.4%+33.6%+36.4%
Return on net worth+13.3%+14.9%+20.3%+17.4%+24.7%+25.9%+28.5%
Debt / equity0.420.310.000.050.070.010.03
Long-term debt / equity0.250.210.000.000.000.000.00
Interest cover22.0518.590.881.982.770.630.94
Efficiency & per share
Fixed asset turnover1.801.862.072.303.314.724.77
Inventory turnover9.548.558.007.077.158.139.45
Debtors turnover10.0611.3313.6816.8717.8314.0417.19
EPS (₹)49.3643.2946.8331.1634.6827.0723.92
Dividend per share (₹)1.000.000.000.000.000.007.55
Book value per share (₹)397.21347.13242.21194.31163.27118.1891.15

To see the full year-wise statements and ratios of Mankind Pharma Limited, buy the company report.

Board of directors of Mankind Pharma Limited

Mankind Pharma has 8 current directors and 18 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Rajeev Juneja
Also directs: Appian Associates Infrastructure Private Limited, Pavi Buildwell Private Limited, Luxor Metaltec India Pvt Ltd and 5 more
Managing Director22 Dec 199233 Years 10 MonthsCurrent
Sheetal Arora
Also directs: Pavi Buildwell Private Limited, Kindcare Foundation, Appian Projects LLP and 5 more
Whole-Time Director21 Sep 200719 Years 1 MonthsCurrent
Tilokchand Punamchand Ostwal
Also directs: T.P.Ostwal & Associates LLP, T P Ostwal Maheshwari & Associates LLP, Polycab India Limited and 5 more
Director01 Jan 20206 Years 9 MonthsCurrent
Vijaya Sampath
Also directs: Ingersoll-Rand (India) Limited, Craftsman Automation Limited, Va Tech Wabag Limited and 4 more
Director01 Aug 20224 Years 2 MonthsCurrent
Satish Kumar Sharma
Also directs: Mankind Consumer Products Private Limited, Appian Properties Private Limited, Bharat Serums and Vaccines Limited and 4 more
Whole-Time Director23 Sep 201610 Years 1 MonthsCurrent
Ramesh Juneja
Also directs: PP & A Combines LLP, Rar Real Estate Properties LLP, Appian Horizon LLP and 5 more
Whole-Time Director03 Jul 199135 Years 3 MonthsCurrent
Showing 6 of 8 current directors. View all directors

Auditor

Mankind Pharma Limited is audited by S.R. Batliboi & CO. LLP for the financial year 2025.

Auditor firmFinancial yearFirm registration number
S.R. Batliboi & CO. LLPFY 2025301003E/E300005

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 72.60%, foreign institutional investors hold 9.40%, domestic institutional investors hold 15.40% and retail and other public shareholders hold 2.60%.

Promoters: 72.60%DII (Domestic Institutional): 15.40%FII (Foreign Institutional): 9.40%Retail & Others: 2.60%
Sep 2026
QUARTER
72.60% Promoters
15.40% DII (Domestic Institutional)
9.40% FII (Foreign Institutional)
2.60% Retail & Others
Promoter holding - history
Now 72.60% · Sep 2026High 72.70% · Dec 2025Low 72.60% · Sep 2026
71%71.8%72.5%73.3%74%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 72.70%Mar 2026: 72.70%Jun 2026: 72.70%Sep 2026: 72.60%72.70%72.60%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters72.60%72.70%72.70%72.70%
Public27.40%27.30%27.30%27.30%

Charges & borrowings

Open charges
₹4,915 Cr
Satisfied charges
₹7,758.37 Cr
Breakdown by lending institutions
Others₹4,060.00 Cr
Hdfc Bank Limited₹355.00 Cr
State Bank of India₹300.00 Cr
Citi Bank N.A.₹200.00 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
14 Nov 2024101005942Others₹1,250 CrOpen
14 Nov 2024101005946Others₹2,500 CrOpen
14 Oct 2024100997549State Bank of India₹300 CrOpen
26 Dec 2023100839353Others₹200 CrOpen
30 Mar 2021100439267Others₹110 CrOpen

To see the full charge records of Mankind Pharma Limited, buy the company report.

Total charge records: 38 View all charges

Deals & funding

Mankind Pharma Limited has 29 deals on record (14 secondary share transfers, 12 market trades, 1 funding round), with disclosed funding of ₹74.05 Cr; the latest was in October 2025.

Total deals
29
Secondary share transfers
14
Market trades
12
Funding round
1
IPO
1
Disclosed funding
₹74.05 Cr

Deals on record (5 of 29)

WhenDealAmountParties
Oct 2025Market trade₹13.37 CrBuyer: Goldman Sachs Bank Europe Se - Odi
Seller: Goldman Sachs (Singapore) Pte - Odi
Oct 2025Market trade₹10.31 CrBuyer: Goldman Sachs Bank Europe Se - Odi
Seller: Goldman Sachs (Singapore) Pte - Odi
May 2025Market trade₹13.39 CrBuyer: Goldman Sachs Public Market Fund
Seller: Copthall Mauritius Investment Limited
Jul 2024Market trade₹768.49 CrBuyer: Morgan Stanley Investment Management, Icici Prudential Mutual Fund A/C Icici Prudential India Opportunities Fund, Icici Prudential Mutual Fund, an individual
Seller: Hema Cipef (I) Limited
Dec 2006Secondary share transferUndisclosedBuyer: 3 individuals
Seller: Mankind Drugs Private Limited , Mediforce Healthcare Private Limited , 2 individuals

To see the full deal history of Mankind Pharma Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME payment delays

Mankind Pharma Limited has 3 MSME Form 1 returns on record between 2021 and 2024, listing 998 overdue payments to 142 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 142)

SupplierAmount dueDue sinceReported on
Synokem Lifesciences Private Limited
N.S. Industries Unit-Ii
Printman
Creative Pharma Technologies Private Limited
Poci Creative LLP

To see the full MSME payment records of Mankind Pharma Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Group structure & subsidiaries

Mankind Pharma has 22 subsidiary companies and 2 associated companies. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.

22
Subsidiary companies
2
Associated companies
Key subsidiaries
Company NameCINShares held
Qualitek Starch Private LimitedU15134HP2019PTC007684
Mankind Medicare Private LimitedU21002DL2023PTC419826
Appian Properties Private LimitedU24100DL2017PTC321898
Mankind Life Sciences Private LimitedU24100DL2020PTC369904
Mankind Consumer Healthcare Private LimitedU24230DL2021PTC388536
Pharmaforce Excipients Private LimitedU24230HP2019PTC007703

To see the full group structure of Mankind Pharma Limited, buy the company report.

Employees & EPFO

Mankind Pharma Limited has a workforce of 19,928 employees on its EPFO records as of Oct 10, 2025, across 3 active EPFO establishments.

Employee count
19,928
Active EPFO establishments
3
Employee growth
0.06%

GST

Mankind Pharma has 35 GST registrations: 29 active and 6 cancelled or inactive. The first 4 active GSTINs are listed below.

Total GSTINs
35
Active
29
Cancelled / inactive
6
GSTINStateStatusRegistered on
07AAACM9401C1ZXDelhiActive01 Jul 2017
07AAACM9401C2ZWDelhiActive14 Sep 2017
02AAACM9401C1Z7Himachal PradeshActive01 Jul 2017
03AAACM9401C1Z5PunjabActive01 Jul 2017

To see the full GST registrations and return filing status of Mankind Pharma Limited, buy the company report.

Recent activity

Mankind Pharma Limited has 40 board changes on record since 1991: 25 appointments and 15 cessations. The latest: Anish Vanraj Bafna was appointed as Director on 10 Aug 2026.

Charges
A charge with Others of Rs. 1,250.00 Cr registered on 14 Nov 2024 with Charge ID 101005942 was modified on 17 Aug 2026.
Charges
A charge with Others of Rs. 2,500.00 Cr registered on 14 Nov 2024 with Charge ID 101005946 was modified on 17 Aug 2026.
Appointed
Anish Vanraj Bafna was appointed as Director.
AGM
Mankind Pharma Limited last Annual general meeting of members was held on 04 Aug 2026 as per latest MCA records.
Charges
A charge with Others of Rs. 110.00 Cr registered on 30 Mar 2021 with Charge ID 100439267 was modified on 29 Jun 2026.
Charges
A charge registered on 07 Sep 2018 via Charge ID 100211107 with Hdfc Bank Limited was fully satisfied on 15 Jun 2026.
Charges
A charge registered on 14 Nov 2024 via Charge ID 101005947 with Others was fully satisfied on 20 May 2026.
Filing
Mankind Pharma Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Delhi I.
Charges
A charge registered on 24 Nov 2025 via Charge ID 101202514 with Citi Bank N.A. was fully satisfied on 18 Feb 2026.
Charges
A charge with Hdfc Bank Limited of Rs. 355.00 Cr registered on 11 Dec 2020 with Charge ID 100401490 was modified on 09 Dec 2025.
Charges
A charge with Citi Bank N.A. amounted to Rs. 106.00 Cr with Charge ID 101202514 was registered on 24 Nov 2025.
Charges
A charge registered on 01 Dec 2022 via Charge ID 100652628 with Hdfc Bank Limited was fully satisfied on 27 Jun 2025.

111 earlier events are in the company report.

News

MANKIND: Q2 CONS NET PROFIT 7.1B RUPEES VS 5.11B (YOY); EST 6.15B
26 Oct 2026 · Exchange Update
MANKIND: Q2 REVENUE 43.4B RUPEES VS 36.97B (YOY)
26 Oct 2026 · Exchange Update
MANKIND: Q2 EBITDA 11.7B RUPEES VS 9.21B (YOY); Q2 EBITDA MARGIN 27% VS 24.92% (YOY)
26 Oct 2026 · Exchange Update
Mankind: Approves Merger Plan For Fully Owned Subsidiaries Prolijune Lifesciences And Pavi Buildwell.
26 Oct 2026 · Exchange Update
Mankind Pharma: Board Approves Investment of Up to €45 Million in Mankind Netherlands and Plans to Buy 70% Stake in Armed Cell Therapeutics for €48 Million.
15 Oct 2026 · Exchange Update
MANKIND: Rs. 46.93 Crores BSE Block Trade; for ~ 196,108 Shares, at Rs. 2393.15
13 Oct 2026 · Exchange Update

From our blog

Frequently asked questions

Mankind Pharma is an active public limited company based in New Delhi, Delhi, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 03 July 1991 (35+ years old) and is registered under CIN L74899DL1991PLC044843. Listed on BSE: 543904 and NSE: MANKIND.

Mankind Pharma reported revenue of ₹14,278 Cr for FY 2025-26 (up 17% YoY) based on consolidated financials.

Mankind Pharma has 8 current directors:

The latest financial statements of Mankind Pharma on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 04 August 2026. Year-wise statements from 2015 are in the company report.

The GSTIN of Mankind Pharma is 07AAACM9401C1ZX, registered in Delhi. The company has 35 GST registrations in all, of which 29 are active and 6 are cancelled or inactive. Other active GSTINs include 07AAACM9401C2ZW (Delhi), 02AAACM9401C1Z7 (Himachal Pradesh), 03AAACM9401C1Z5 (Punjab).

The CIN (Corporate Identification Number) of Mankind Pharma is L74899DL1991PLC044843. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Mankind Pharma is a listed company as per MCA records. Its shares are listed on both BSE (code: 543904) and NSE (symbol: MANKIND).

Mankind Pharma has 622 court cases on record: 537 filed by the company and 85 filed against it. 232 are pending. Most are in the high courts.

Mankind Pharma was incorporated on 03 July 1991, making it 35+ years old. It is registered with the Registrar of Companies, Delhi.

Mankind Pharma has 29 deals on record (14 secondary share transfers, 12 market trades, 1 funding round), with disclosed funding of ₹74.05 Cr; the latest was in October 2025.

Anish Vanraj Bafna was appointed as Director on 10 Aug 2026. Surendra Lunia ceased to be Director on 18 Feb 2025. Hitesh Kumar Jain was appointed as Company Secretary on 20 Jan 2025. Mankind Pharma has 40 board changes on record in total.